1. Introduction {#s0005}
===============

Multi-target drugs (MTDs) interact with several biological substances. This type of approach is categorized under polypharmacology ([@b0305]), and offers better efficacy, fewer side effects and decreased vulnerability to adaptive resistance ([@b0270]). Studies have shown that drugs interacting with multiple targets have a safer profile as compared to single-target drugs ([@b0030]). MTDs are well suited for complex diseases, which are controlled by several intrinsic and extrinsic factors acting together to drive the onset and progression of these diseases ([@b0260]). Indeed, several MTDs are already on the market, such as lapatinib (Tykerb) for treating breast cancer ([@b0210]). Ladostigil, an MTD against neurodegenerative diseases has shown potential and is under investigation ([@b0195]). However, other complex metabolic diseases such as osteoporosis lack potent candidates for MTD development.

Osteoporosis constitutes one of the top health issues that hampers everyday functioning and poses a huge economic burden on the patients. The disease is characterized by weak and fragile bones, and low bone mineral density. Drugs available to combat osteoporosis are associated with adverse effects and are unable to improve the formation of new bone ([@b0070]). More importantly, most of the osteoporosis drugs are also single-targeted. Therefore, the need to identify more effective drugs that have fewer side effects, can enhance bone formation, and target multiple pathways is dire. MTDs also have an advantage over the usage of multiple drugs for single pathological condition, as drug-drug interaction might have severe outcomes in some cases ([@b0140]). For osteoporosis, co-administration of bisphosphonates with calcium supplements, or any oral medication containing divalent cation hinders the absorption of bisphosphonates and increases the risk of fracture in such patients ([@b0265]). Therefore, identifying active agents that have multiple molecular mechanisms involved in bone formation as their target is necessary.

Bone tissue undergoes remodeling throughout life to maintain its volume and mineral homeostasis ([@b0090]). Several regulatory signals and interacting factors influence the process of bone cell differentiation and bone remodeling ([@b0235]). At sites of remodeling, osteoblasts form new bone, whereas osteoclasts dissolve existing bone ([@b0255]). Osteoblasts undertake the production of bone matrix proteins, collagen type 1 (Col-1), which constitutes 90% of extracellular matrix (ECM) proteins. Bone sialoprotein (BSP), osteocalcin, osteonectin, and several other proteoglycans, are involved in the process of mineralization ([@b0015]). BMPs are closely involved in the expression of alkaline phosphatase (ALP), which also stimulates mineral deposition ([@b0110], [@b0155]). Certain factors from osteoblasts control bone remodeling by influencing the rate of osteoclast formation. Binding of two factors produced by osteoblast, receptor activator of nuclear factor (NF)-κB ligand (RANKL) and osteoprotegerin (OPG) prevents the maturation and activation of osteoclast cells ([@b0135]). Autophagy is a cellular process involved in regulating the physiological function and survival of osteoblasts ([@b0355]). This cellular process protects osteoblasts from the stress caused by toxic stimuli and superoxides ([@b0240]). All these essential molecules and their signaling mechanisms, together, contribute to the process of bone remodeling and thus can serve as suitable targets for therapeutic interventions against osteoporosis.

Plants are a rich source of secondary metabolites possessing medicinal properties. Their potential against neurodegeneration, cancer, oxidative stress, and skeletal disorders has been extensively established ([@b0100], [@b0115]). One such example is the plants from genus *Euonymus;* they are rich in medicinal properties and are also well known for their traditional uses. *E. alatus* is used traditionally against cancer, and is also used for pain relief and blood circulation in folk medicine ([@b0280]). Studies reported that *E. alatus* possesses anti-diabetic, anti-oxidant and anti-cancer potential ([@b0050], [@b0055]). Other plants of the genus, like *E. japonicus,* possess anti-viral activity ([@b0315]), and compounds isolated from this plant act as acetylcholinesterase inhibitors ([@b0005]). *E. laxiflorus* is reported to inhibit α-glucosidase ([@b0220]) and α-amylase ([@b0215]). *E. fortunei* and *E. hederaceus* reportedly possesses anti-oxidant activity ([@b0225], [@b0275], [@b0290]). During preliminary screening of certain native Taiwanese plants, we found that *E. spraguei* Hayata from family Calestraceae possesses osteogenic potential. A supporting study found that celastrol, a compound isolated from traditional Chinese medicine belonging to family Calestraceae significantly attenuates bone loss in mice with collagen-induced arthritis ([@b0080]).

The present study aims to isolate and identify the active compounds of *E. spraguei,* followed by elucidating their osteogenic potential and possible underlying mechanisms using human osteoblast (HOb) cells as an experimental model.

2. Materials and methods {#s0010}
========================

2.1. Extraction and compound isolation {#s0015}
--------------------------------------

Stems of *E. spraguei* (ES) were collected from Yuang-feng Mountain (Nantou, Taiwan) and the specimen was identified by Dr. Ih-Sheng Chen, College of Pharmacy, Kaohsiung Medical University (Kaohsiung, Taiwan). Following this an herbarium specimen voucher numbered M404 was assigned and deposited in the Graduate Institute of Pharmacognosy, Taipei Medical University (Taipei, Taiwan). Dried and crushed stems of ES (3.07 kg) were exhaustively extracted with 30 L of 95% ethanol for seven days (twice), and the resulting solution was vacuum evaporated to yield 96.08 g of a crude ES extract. Water was used to re-suspend ES extract followed by successive partitioning with *n*-hexane (H), ethyl acetate (E) and *n*-butanol (B), to yield ES-H (9.48 g), ES-E (3.81 g), ES-B (9.37 g) and aqueous (ES-A, 53.2 g) fractions.

The ES-E fraction was subjected to Diaion HP-20 (250--850 μm, Merck KGaA, Darmstadt, Germany) column chromatography using H~2~O to MeOH as the mobile phase, and seven major sub-fractions (ES-E-1-1 \~ ES-E-1-7) were collected. ES-E-1-5 (0.51 g) and ES-E-1-6 (0.71 g) were combined and subjected to the Sepbox 2D-2000 system ([@b0350]) (Sepiatec, Germany). This sample was transferred to an injection column and 18 fractions were collected using separation column I, a C-4 reverse-phase (RP) column. Further on, these fractions were transferred to solid-phase extraction (SPE) columns. Fractions present in each SPE column were then passed through separation column II, C-18 RP-high performance liquid chromatography (HPLC) for subsequent separation. Solvents different from those used during the first fractionation were used for elution. In total,176 individual sub-fractions (vials 1--176) were collected. ES-E-1-5,6-v11 was subsequently purified by an RP- HPLC column (Phenomenex Luna penta fluoro phenyl (PFP), 5 μm, 10 × 250 mm; Torrance, CA, USA) with 70% MeOH at a flow rate of 3 ml/min to collect compound **1** (1.5 mg) at 11 min.

The ES-B fraction was also passed through Diaion-HP (250--850 μm) column chromatography with H~2~O to MeOH as the mobile phase, and seven major fractions (ES-B-1-1 \~ ES-B-1-7) were collected. Major fraction ES-B-1-3 (2.09 g) was subjected to C-18 column (75 µm, Nacalai Tesque, Kyoto, Japan) using H~2~O to MeOH as the eluent, and 12 sub-fractions (ES-B-1-3-1 \~ ES-B-1-3-12) were collected. ES-B-1-3-10 was chromatographically purified by RP-HPLC column (Phenomenex Luna PFP, 5 μm, 10 × 250 mm) with 30% MeOH and at retention time of 15 min and flow rate 3 ml/min to collect compound **2** (2.8 mg). ES-B-1-3-11 was purified using RP-HPLC columns with 35% MeOH at 11 min and Phenomenex Luna PFP (5 μm, 10 × 250 mm) using 40% MeOH at a retention time of 11 min and a flow rate of 3 ml/min to collect compound **3** (3.1 mg).

2.2. Cell culture {#s0020}
-----------------

We purchased primary human osteoblasts (HObs), osteoblast growth medium (OGM) and osteoblast differentiation medium (ODM) from Cell Applications (San Diego, USA). To obtain fully differentiated HOb cells, ODM, with dexamethasone, ascorbic acid and β-GP for mineralization was used, which is indicated as ODM miner hereafter ([@b0100], [@b0185]). Puerarin was used as a positive control in this study, as it is reported to possess osteogenic potential ([@b0320]).

2.3. Cell viability analysis {#s0025}
----------------------------

HOb cells were seeded and treated with samples (isolated compounds at 100 µM and puerarin as the positive control at 1 µM) for five days. MTT assay was conducted to measure cell viability at an absorbance of 600 nm ([@b0185]).

2.4. ALP activity {#s0030}
-----------------

HOb cells (4 × 10^3^/well) were seeded using OGM. The following day, OGM containing samples at various indicated concentrations was added and treated for three days. Following this cells were washed and lysed with PBS and 0.1% Triton X-100, respectively. ALP activity was measured with *p*-nitrophenyl phosphate (dissolved in 6 mM sodium bicarbonate-sodium carbonate buffer, pH10.0) and bicinchoninic acid (BCA) protein using a BCA protein assay kit (Thermo Fisher Scientific), reaction was incubated at 37 °C for 1 h. After this ODs were measured and ALP activity was determined by normalizing ALP values to BCA values ([@b0185]).

2.5. Alizarin red S staining {#s0035}
----------------------------

HOb cells were seeded using OGM, and 72 h later, samples were added. This was followed by the continuous treatment of samples in ODM miner every two days. After 11 days, mineralization assay was done according to [@b0100].

2.6. RNA isolation and real-time quantitative polymerase chain reaction {#s0040}
-----------------------------------------------------------------------

HOb cells were seeded using OGM, and the next day, samples were added. Cells were collected the following day and total cellular RNA was isolated using a High pure RNA isolation kit from Roche Life Science (Mannheim, Germany). In order to synthesize cDNA, a high-capacity cDNA reverse-transcription kit from Thermo Fisher Scientific was used.

A Roche™ Universal probe llibrary (UPL) probe and SYBR green master mix (Roche Life Science) including the SensiFAST™ probe no-ROX kit (Bioline, London, UK) were used for PCR amplification with the LightCycler® 480 system (Roche Life Science). Sequences of primers used are shown in [Table 1](#t0005){ref-type="table"}. Gene expression levels were calculated by the 2^(−ΔΔCt)^ method, Livak formula, and normalized against GAPDH and expressed relative to the control ([@b0100]).Table 1Primer and probe combination used for the real-time PCR.Sequence (5′ → 3′)Probe NumberRunx-2Forward\
ReverseCAGTGACACCATGTCAGCAA\
GCTCACGTCGCTCATTTTG41BMP-2Forward\
ReverseCGGACTGCGGTCTCCTAA\
GGAAGCAGCAACGCTAGAAG49BSPForward\
ReverseGATTTCCAGTTCAGGGCAGT\
TCTCCTTCATTTGAAGTCTCCTCT63Col-1Forward\
ReverseAGGTCCCCCTGGAAAGAA\
AATCCTCGAGCACCCTGA60GAPDHForward\
ReverseAGCCACATCGCTCAGACAC\
GCCCAATACGACCAAATCC60RANKLForward\
ReverseCGTTGGATCACAGCACATCAG\
GTACCAAGAGGACAGACTCACn.aOPGForward\
ReverseCACTACTACACAGACAGCTGG\
ACTCTATCTCAAGGTAGCGCCn.a

2.7. Estrogen receptor (ER) expressions {#s0045}
---------------------------------------

HOb cells were seeded, and 24 h later OGM containing samples was added and treated for five days. Expression levels of ERs were detected using an ESR cell-based ELISA kit (Abnova, CA, USA) according to [@b0100].

2.8. Western blot analysis {#s0050}
--------------------------

HOb cells were seeded and 24 h later samples were added. After three days, cells were collected and lysed. Protein concentrations were measured and sodium dodecyl sulfate polyacrylamide gel electrophoresis was done to separate cell lysates. Lysates were transferred to polyvinylidene difluoride membranes, followed by probing with primary antibodies. Mouse anti-OPN and rabbit-anti TGF-β were purchased from GeneTex Inc. and were used at dilutions 1:1000. Rabbit anti-LC3I and LC3II were purchased from Thermo Fisher Scientific and were used at dilutions 1:1000. Rabbit anti-pSmad 1/5/8 were used at the dilutions of 1:500 and were purchased from Santa Cruz Biotechnology (CA, USA). Rabbit anti-β-actin was purchased from Abcam and was used at dilutions of 1:500. Secondary antibodies, goat anti-mouse IgG HRP from Thermo Fisher Scientific at 1:3000 and goat anti-rabbit IgG H&L HRP from Abcam at 1:3000 were used ([@b0300]).

2.9. Statistical analysis {#s0055}
-------------------------

SigmaPlot version 11.0, developed by SYSTAT (IL, USA) was used to conduct all statistical analysis. The values represent mean ± standard deviation (S.D). A one-way analysis of variance (ANOVA) with Student-Newman-Keuls test was conducted and *p* \< 0.05 was considered statistically significant.

3. Results {#s0060}
==========

3.1. Isolation and identification of compounds {#s0065}
----------------------------------------------

The ES extract was subjected to a series of chromatographic columns including Sepabox for separation, purification, and isolation. After using various spectroscopic techniques and literature comparison, we identified the isolated compounds to be syringaresinol (**1**) ([@b0145]), syringin (**2**) ([@b0230]), and (−)-epicatechin (**3**) ([@b0075]) ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Structure of compounds isolated from *E. spraguei.*

3.2. Effect of syringin (**2**) and (−)-epicatechin (**3**) on the viability of HOb cells {#s0070}
-----------------------------------------------------------------------------------------

Prior to analyzing the activity of the isolated compounds, their effect on cell viability was studied. Results showed that both **2** and **3** at 100 µM exerted negligible effect on the cell viability of HObs, as cell viability was above 80% ([Fig. 2](#f0010){ref-type="fig"}A).Fig. 2Effect of syringin (**2**) and (−)-epicatechin (**3**) on the cell viability and ALP activity in HOb cells. Cells were seeded in 96-well plate and after 24 h samples were added using OGM. After 5 days (**A**) MTT was added and incubated for 4 h, after which cell viability was detected. (**B**) To analyze ALP activity, assay was performed and normalized by BCA. Results are from three independent repeats with errors bars indicating the mean ± standard deviation (SD), \**p* ≤ 0.05, \*\**p* ≤ 0.01 compared to the control.

3.3. Effect of syringin (**2**) and (−)-epicatechin (**3**) on ALP activity in HOb cells {#s0075}
----------------------------------------------------------------------------------------

ALP, a biomarker of bone formation and one of the key factors that directly induce deposition of minerals such as calcium and phosphate in bone ([@b0200]), was examined. Results showed that **2** increased ALP activity to 113.24% and 131.01% at 80 and 100 µM respectively. Similar results were observed wherein **3** significantly increased ALP activity to 111.17% and 130.67% at 80 and 100 µM, respectively. Taken together, these results showed that **2** and **3** concentration-dependently increased ALP activity to a similar degree ([Fig. 2](#f0010){ref-type="fig"}B).

3.4. Effect of syringin (**2**) and (−)-epicatechin (**3**) on mineral deposition in HOb cells {#s0080}
----------------------------------------------------------------------------------------------

Mineralization is the quintessential outcome of bone formation in which mineral crystals are deposited in an organized manner onto the organic ECM ([@b0035]). Our results showed that **2** and **3**, even at the lowest doses tested, significantly increased mineral deposition in HOb cells. **2** at 60, 80, and 100 µM respectively increased mineralization to 112.05%, 125.32%, and 139.39%. Similar results were observed for **3** in which the increase in levels of mineralization was up to 116.83%, 127.87%, and 138.33% at 60, 80 and 100 µM, respectively ([Fig. 3](#f0015){ref-type="fig"}). These results demonstrated that both **2** and **3** induce mineralization in the HOb cells, and combined with the ALP activity results, indicate the osteogenic potentials of these compounds. We next sought to elucidate the potential underlying mechanism(s) through which these compounds induce bone formation.Fig. 3Effect of syringin (**2**) and (−)-epicatechin (**3**) on mineral deposition in HOb cells. Cells were seeded in a 48-well plate and after 3 days, samples were added to cells using ODM miner. Following this samples at different doses with the promoter and inducer were added for the next 11 days using ODM miner. After that mineralization was detected using (**A**) Alizarin red staining and (**B**) quantification was done by de-staining. Results are from three independent repeats with errors bars indicating the mean ± standard deviation (SD), \*\**p* ≤ 0.01 compared to the control.

3.5. Effect of syringin (**2**) and (−)-epicatechin (**3**) on expression of ERs in HOb cells {#s0085}
---------------------------------------------------------------------------------------------

ER-α is correlated with the bone mass in humans, as it is reported that the protection of cortical bone mass by estrogens is mediated via ER-α. Independent of estrogens, ER-α is also essential for bone formation, as it stimulates Wnt signaling ([@b0125], [@b0180]). However, ER-β works antagonistically to ER-α ([@b0125]). We examined the effect of **2** and **3** on expression levels of these receptors. Our results showed that 100 µM of **2** significantly increased the expression level of ER-α up to 113.42%, it also attenuated the expression of ER-β down to 91.99%. In contrast, **3** exerted no significant effect on the expression ER-α and -β ([Fig. 4](#f0020){ref-type="fig"}).Fig. 4Effect of syringin (**2**) on ERs. Cells were seeded in a 96-well plate and after 24 h, samples were added to cells using OGM. After 5 days, expression levels of estrogen receptors were detected by an ELISA using an ESR (Human) Cell-based ELISA kit from Abnova following the manufacturer's instructions. Results are from three independent repeats with errors bars indicating the mean ± standard deviation (SD), \**p* ≤ 0.05, \*\**p* ≤ 0.01 compared to the control.

3.6. Effect of syringin (**2**) and (−)-epicatechin (**3**) on expression levels of key genetic markers in HOb cells {#s0090}
--------------------------------------------------------------------------------------------------------------------

Bone formation is regulated by several genetic factors and signaling cascades. We examined the effect of isolated compounds (at 100 µM) on some key genes and transcription factors involved in the process of bone remodeling. Our results showed that **2** increased the mRNA expression levels of BMP-2, Col-1, BSP and Runx-2 up to 2.58, 1.43, 3.05 and 2.32 folds, respectively. The respective fold increase induced by **3** was up to1.93, 2.55, 1.58, and 1.68 for BMP-2, BSP, Col-1, and Runx-2 ([Fig. 5](#f0025){ref-type="fig"}A--D). In addition, **2** and **3** enhanced the mRNA expression levels of OPG/RANKL to 2.99 and 2.12 folds, respectively ([Fig. 5](#f0025){ref-type="fig"}E). These results demonstrated that **2** and **3** increased mRNA expression levels of several important genes implicated in bone formation, including BMP-2 pathway-associated genes (BMP-2, BSP, and Runx-2), suggesting that the osteogenic activity of these compound is mediated via the BMP-2 pathway.Fig. 5Effect of syringin (**2**) and (−)-epicatechin (**3**) on bone formation-related genes HOb cells. Cells were seeded in 6-cm dishes and after 24 h, fresh ODM containing 100 µM of **2** and **3** was added. After 24 h cells were collected, followed by mRNA isolation and reverse transcription. Expression levels of (**A**) BMP-2, (**B**) BSP, (**C**) Col-1, (**D**) Runx2 and (**E**) OPG/RANKL were detected by performing a real-time PCR. Results are from three independent repeats with errors bars indicating the mean ± standard deviation (SD), \**p* ≤ 0.05, \*\**p* ≤ 0.01 compared to the control.

3.7. Effect of syringin (**2**) and (−)-epicatechin (**3**) on BMP-2 signaling in HOb cells {#s0095}
-------------------------------------------------------------------------------------------

To further substantiate the effect of the BMP-2 pathway in the osteogenic activity of the compounds, we conducted a Western blot analysis against BMP-2 pathway-associated proteins. Our results showed that at 100 µM, **2** and **3** significantly increased expression levels of BMP-2 pathway-associated proteins, TGF-β and pSmad 1/5/8 ([Fig. 6](#f0030){ref-type="fig"}A--C). To further confirm the involvement of BMP-2 in mediating osteogenic activity by **2** and **3**, we inhibited BMP-2 using the inhibitor dorsomorphin (20 µM for 72 h) and analyzed ALP activity. Results showed that in the presence of the inhibitor, levels of ALP activity dropped significantly, ([Fig. 6](#f0030){ref-type="fig"}D). Together, these results indicated that **2** and **3** induce osteogenesis through the BMP-2 pathway.Fig. 6Syringin (**2**) and (−)-epicatechin (**3**) mediates their effect *via* BMP-2 signaling pathway. Cells were seeded in 6 cm plates and after 24 hr treated with **2** and **3** at 100 µM for 3 days. (**A**) Cell lysates were collected and examined by a Western blot analysis to detect protein expression levels of TGF-β and pSmad 1/5/8. (**B** and **C**) Densitometry of A. To confirm that **2** and **3** mediate their osteogenic effect through the BMP-2 pathway we used the BMP-2 inhibitor, (**D**) dorsomorphin at 20 µM and analyzed its effect on ALP activity. Results are from three independent repeats with errors bars indicating the mean ± standard deviation (SD), \**p* ≤ 0.05, \*\**p* ≤ 0.01 compared to the control.

3.8. Effect of syringin (**2**) and (−)-epicatechin (**3**) on autophagy in HOb cells {#s0100}
-------------------------------------------------------------------------------------

Autophagy is essential for mineral deposition as studies have reported that loss of autophagy proteins resulted in decreased bone volume ([@b0240]). Once autophagy is induced, the essential autophagy protein microtubule-associated protein 1 light chain 3 (LC3I) becomes lipidated (LC3II). The conversation of LC3I to LC3II is the hallmark of autophagy. To examine if **2** and **3** (at 100 µM) modulate autophagy, we quantified protein levels of LC3II using Western blotting. Results showed that whereas **2** significantly induced autophagy, indicated by a substantial increase in LC3II expression, **3** decreased the expression of LC3II, indicating that **2**, but not **3**, induced autophagy ([Fig. 7](#f0035){ref-type="fig"}A and B). To understand the role of autophagy, we inhibited autophagy with bafilomycin (50 nM for 10 h), an inhibitor of autophagosome maturation. Results showed that inhibition of autophagy significantly decreased the **2**-mediated increase in ALP activity. In contrast, as expected, inhibition of autophagy did not significantly affect the **3**-mediated increase in ALP activity ([Fig. 7](#f0035){ref-type="fig"}C). These results showed that **2**, induces ALP activity also through the autophagy pathway.Fig. 7Modulation of autophagy by syringin (**2**) and (--)-epicatechin (**3**) in HOb cells. Cells were seeded in 6 cm plates and after 24 h treated with **2** and **3** at 100 µM for 3 days. (**A**) Cell lysates were collected and examined by a Western blot analysis to detect protein expression levels of LC3I and LC3II. (**B**) Densitometry of A. To confirm the association of autophagy in the osteogenic potential of **2** and **3**, (**C**) autophagy was inhibited using bafilomycin (50 nM) and ALP activity was determined. Results are from three independent repeats with errors bars indicating the mean ± standard deviation (SD), \*\**p* ≤ 0.01 compared to the control.

3.9. Effect of syringin (**2**) and (−)-epicatechin (**3**) on osteopontin (OPN) expression in HOb cells {#s0105}
--------------------------------------------------------------------------------------------------------

OPN, is an important non-collagenous protein that affects bone material properties and is involved in damage repair. Studies have shown that loss of OPN results in the loss of bone toughness, as it also regulates bone structure and morphology ([@b0020], [@b0040]). We wanted to analyze if **2** and **3** at 100 µM regulate the expression level of OPN. Results showed that both **2** and **3** significantly upregulated OPN expression ([Fig. 8](#f0040){ref-type="fig"}).Fig. 8Induction of OPN by syringin (**2**) and (−)-epicatechin (**3**) in HOb cells. Cells were seeded in 6 cm plates and after 24 h, were treated with **2** and **3** at 100 µM for 3 days. Cells lysates was collected and examined by a Western blot analysis to detect protein expression levels of (**A**) OPN (**B**) Densitometry of A. Results are from three independent repeats with errors bars indicating the mean ± standard deviation (SD), \*\**p* ≤ 0.01 compared to the control.

4. Discussion {#s0110}
=============

The process of bone remodeling involves the removal of old and damaged bone, followed by the formation of new bone. Any imbalance in this process result in the onset of disorders like osteopenia and osteoporosis ([@b0120]). These conditions are highly refractive to treatments due to clinically unmet needs. Plants and compounds derived from them possess medicinal potential for drug discovery against conditions like osteoporosis ([@b0205]). Numerous studies have discovered that plants and their compounds can enhance bone formation ([@b0085], [@b0335]). Our study is the first to introduce *Euonymus spraguei* as a plant that possesses osteogenic potential. In this study, we extracted stems of *E. spraguei* using 95% ethanol and isolated three compounds. The osteogenic potential of two of these isolated compounds was analyzed by examining their effect on biomarkers of bone formation. We also explored the possible underlying mechanisms responsible for their osteogenic potential by studying their interaction with various signaling pathways.

Syringin (**2**), is a phenolic glycoside belonging to eleutheroside derivatives. **2** was reported to possess certain pharmacological properties ([@b0175]), including antioxidant activity ([@b0130], [@b0170]), anti-diabetic effect ([@b0150]), anti-allergic effect ([@b0060]), protection against neuronal cell damage ([@b0340]), anti-inflammatory effect ([@b0060], [@b0065]), and inhibition of apoptosis ([@b0340]). However, the osteogenic activity of **2** has not been extensively explored. A recent study reported that **2** prevented bone loss in ovariectomized mice by inhibiting osteoclastogenesis ([@b0165]), without having any significant effect on ALP activity. In contrast to this study, we show here that **2** concentration-dependently induced ALP activity in HOb cells ([Fig. 2](#f0010){ref-type="fig"}B). The reason behind the varying results of ALP activity could be due to differences in the experimental models, as other authors collected total protein from the bone of mice which included all bone cells whereas we analyzed ALP activity using HOb cells. Nonetheless, the finding that **2** can prevent osteoclastogenesis and enhance osteogenesis makes it an ideal starting-point material for development of a therapeutic strategy to enhance bone formation.

(−)-Epicatechin (**3**) belongs to the family of flavonoids that has diverse health benefits in humans. **3** also possesses numerous biological activities such as antitumor, antimicrobial, antioxidant, anti-inflammatory, neuroprotective and cardio protective activities ([@b0250]). A recent study reported that **3** rich *Marindo citrifolia* extract, ameliorated bone formation, strength and integrity in osteoarthritic rats through anti-inflammatory and anti-oxidative pathways ([@b0310]). Concordantly, our results indicated that **3** significantly increased ALP activity ([Fig. 2](#f0010){ref-type="fig"}B), a key biomarker of bone formation as well as the deposition of minerals in HOb cells ([Fig. 3](#f0015){ref-type="fig"}). Various derivatives and isomers of **3** have also been reported to enhance bone formation ([@b0025]), (−)-epicatechin-3-O-β-[d]{.smallcaps}-allopyranoside reduced arthritis severity score and prevented bone loss in collagen-induced arthritis mice ([@b0095]). A study reported that (−)-epicatechin gallate stimulated osteoblast differentiation through Runx2 transcriptional activation ([@b0045]). Similarly, in our study, **3** significantly increased mRNA expression of Runx2, as well as BSP, a gene found downstream in the associated cascade ([Fig. 5](#f0025){ref-type="fig"}D and B). These results including our study clearly indicate the potential of **3** as bone formation-enhancing constituent.

BMP signaling plays an essential role in embryonic skeletal development as well as bone formation and homeostasis. BMP-2, a member of the BMP family is fundamental for osteoblast differentiation ([@b0325]). A recent study showed that Guhong injection (GHI), a traditional compound preparation with **2** as one of its effective components, significantly increased BMP-2 and TGF-β expression levels ([@b0295]). In parallel with that finding, we also showed that **2** and **3** enhanced expressions of BMP-2-associated proteins at both the mRNA ([Fig. 5](#f0025){ref-type="fig"}A, B and D) and protein levels ([Fig. 6](#f0030){ref-type="fig"}A and C). More importantly, pharmacological inhibition of BMP-2 activity significantly hampered **2**- and **3**-induced ALP activity ([Fig. 6](#f0030){ref-type="fig"}D), indicating the significance of the BMP-2 pathway in the osteogenic potential of these compounds. In agreement with our finding, Aoki et al. showed that BMP-2 is required for the induction of ALP activity ([@b0010]).

RANKL produced by osteoblasts on binding to its receptor RANK (present on osteoclast precursor cells), leads to the fusion of these cells, thereby forming multi-nucleated cells, which further differentiate into mature osteoblasts ([@b0105]). However, a soluble decoy OPG produced by osteoblast binds to RANK, limiting excessive formation of mature osteoclasts ([@b0190]). A study showed that **2** inhibited osteoclast formation ([@b0160]), and also prevented RANKL-induced osteoclast formation of bone marrow macrophages ([@b0285]). This is in agreement with our study, as our results showed that both **2** and **3** increased the mRNA expression level of OPG and subsequently decreased the level of RANKL, thus elevating the OPG/RANKL ratio ([Fig. 5](#f0025){ref-type="fig"}E), which indicates inhibition of osteoclast differentiation and activation.

Autophagy is involved in osteoimmunology, bone homeostasis and mineralization ([@b0240], [@b0355]). SNPs in autophagy-related genes were found to directly influence the bone mineral density ([@b0245]). Studies reported that deposition of minerals by BMP-2 in MC3T3-E1 cells significantly decreased in the presence of an autophagy inhibitor ([@b0330]). Our results indicated that treatment with **2** robustly induced autophagy in HOb cells, as demonstrated by a significant increase in the LC3II level. Interestingly, in contrast to **2**, **3** inhibited autophagy in HOb cells ([Fig. 7](#f0035){ref-type="fig"}A and B). Consequently, inhibition of autophagy through bafilomycin treatment only attenuated **2**- but not 3-induced ALP activity ([Fig. 7](#f0035){ref-type="fig"}C). Precisely how autophagy enhances osteogenesis was unclear in a study by [@b0240]. However, a previous study done on osteoblast-like cells reported that inhibition of autophagy resulted in increased oxidative stress and stimulation of apoptosis, suggesting that autophagy attenuates oxidative stress and maintains cell survival ([@b0345]). Given the role of autophagy in attenuating oxidative stress, it is plausible to speculate that autophagy could enhance osteogenesis by decreasing oxidative stress. Further research is needed to clarify the exact mechanism through which autophagy enhances osteogenesis in HOb cells.

5. Conclusions {#s0115}
==============

Our study is the first to report isolation of compounds and pharmacological activity of *E. spraguei*. We showed that the active constituents, syringin (**2**) and (−)-epicatechin (**3**) obtained from *E. spraguei* elevated ALP activity and mineralization by targeting several pathways, including the ERs, BMP-2, and autophagy signaling. Our findings suggest that *E. spraguei* has osteogenic potential and its active agents can be considered for further investigations as MTD candidates for bone formation.
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